TTX-030 Single Agent and in Combination With Immunotherapy or Chemotherapy for Patients With Advanced Cancers

PHASE1CompletedINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

April 10, 2019

Primary Completion Date

November 30, 2022

Study Completion Date

September 29, 2023

Conditions
Solid TumorLymphoma
Interventions
DRUG

TTX-030

Variable dose and schedule

DRUG

Pembrolizumab

Dose and schedule per standard of care

DRUG

Gemcitabine

Dose and schedule per standard of care

DRUG

nab paclitaxel

Dose and schedule per standard of care

Trial Locations (16)

10032

Columbia University Irving Medical Center, New York

10065

Memorial Sloan Kettering Cancer Center, New York

10461

Montefiore Medical Center, The Bronx

15232

UPMC Hillman Cancer Center, Pittsburgh

33136

Sylvester Comprehensive Cancer Center, Miami

37203

Sarah Cannon Research Institute, Nashville

38138

West Cancer Center and Research Institute, Germantown

40202

Norton Cancer Institute, Louisville

44122

University Hospitals Cleveland Medical Center, Cleveland

68130

Nebraska Cancer Center Oncology Hematology West P.C., Omaha

78229

NEXT Oncology, San Antonio

84112

Huntsman Cancer Intitute, Salt Lake City

92868

UC Irvine Cancer Center, Orange

94143

University of California, San Francisco, San Francisco

95817

UC Davis Comprehensive Cancer Center, Sacramento

08903

Rutgers Cancer Institute of New Jersey, New Brunswick

All Listed Sponsors
lead

Trishula Therapeutics, Inc.

INDUSTRY

NCT03884556 - TTX-030 Single Agent and in Combination With Immunotherapy or Chemotherapy for Patients With Advanced Cancers | Biotech Hunter | Biotech Hunter